2023 World Conference on Lung Cancer (Posters)-EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study

EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study - PDF(Slides)

Back to course

Pdf Summary

A recent study evaluated the efficacy and safety of anlotinib as a maintenance therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC). Anlotinib, which is commonly used as a third-line or beyond-treatment option for this type of cancer, was investigated in the context of maintenance therapy following induction chemotherapy.<br /><br />A total of 27 ES-SCLC patients were enrolled in the study, with 3 subsequently deemed ineligible. Eligible patients who were in stable condition after first-line chemotherapy were given oral anlotinib for a specified period. The primary endpoint was the median progression-free survival (mPFS), while secondary endpoints included the median duration of response (mDOR), median overall survival (mOS), and safety.<br /><br />The results showed a median progression-free survival of 252 days and a median duration of response of 126 days. However, the median overall survival was not reached at the time of the study, as only 7 patients had reached that point. The primary treatment-related adverse events included hypertension, fatigue, and poor appetite, among others. Despite these adverse reactions, patients generally tolerated the treatment well and had a favorable prognosis. Importantly, no patients required a dose reduction due to the severity of adverse events.<br /><br />Overall, anlotinib demonstrated efficacy and manageable safety as a maintenance therapy for ES-SCLC. The study provided evidence-based support for the use of anlotinib as a viable maintenance treatment option for patients with this type of cancer. This research contributes to expanding the available treatment options and improving clinical treatment regimens for patients with ES-SCLC.

Asset Subtitle

Fanming Kong

Meta Tag

Speaker Fanming Kong

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

anlotinib

maintenance therapy

extensive-stage small-cell lung cancer

ES-SCLC

efficacy

safety

induction chemotherapy

progression-free survival

duration of response

overall survival